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Hepatoblastoma is a malignant liver tumour most often found in
infancy, with an incidence of 0.5–1.5 cases per million children
(Perilongo and Shafford, 1999), although several cases of hepato-
blastoma have also been reported for adults (Kuniyasu et al, 1996;
Ahn et al, 1997; Parada et al, 1997). Whilst many cases of hepato-
blastoma are sporadic, there are some familial inherited disorders
of increased growth, most notably Beckwith–Wiedemann (BWS),
for which there is a greatly increased chance of developing hepato-
blastoma (Perilongo and Shafford, 1999). Congenital hepato-
blastomas have also been reported, and are suggested to be a
separate entity, distinct from hepatoblastomas which developed
after neonatal age (Doss et al, 1998; Ammann et al, 1999).
The prognosis for affected children has improved dramatically
following the introduction of preoperative chemotherapy with
overall three year survival rates of 62–70% regardless of the
modality used (Perilongo and Shafford, 1999). Several cytogenetic
studies on hepatoblastomas have been described. Two cases of
hepatoblastoma have been reported for children born with consti-
tutional trisomy 18 (Bove et al, 1996; Teraguchi et al, 1997). Some
of the most frequent constitutional changes observed in hepato-
blastoma include: Trisomies 2, 7, 8, 19, and 20 (Mascarello et al,
1990; Tonk et al, 1994; Swarts et al, 1996; Sainati et al, 1998;
Nagata et al, 1999; Park et al, 1999). The most frequent genetic
abnormalities observed include loss of heterozygosity (LOH) in
chromosomes 1 p and 11 p, and alterations to 2 q (Fletcher et al,
1991; Rodriguez et al, 1991; Anneren et al, 1992; Albrecht et al,
1994; Montagna et al, 1994; Kraus et al, 1996).
Less frequent cytogenetic changes have also been reported.
These include translocations between the long arms of chromo-
somes 1 and 4 (Douglass et al, 1985; Schneider et al, 1997), a
translocation between 1q and 14p (Park et al, 1999), insertion of
2q into 9p (Balogh et al, 1998) and others (reviewed in Nagata
et al, 1999).
In an attempt to further define potential genetic regions of
interest in hepatoblastomas, we have analysed a series of samples
from two different ethnic backgrounds, Caucasian and Japanese,
for numerical genomic imbalances using comparative genomic
hybridization (CGH).
MATERIALS AND METHODS
Samples
A total of eighteen sporadic hepatoblastoma tumour biopsies were
analysed (Table 1). Informed consent from the parents and
approval for the study was granted by the local ethical committees.
Eleven of the tumours were from patients of Caucasian origin
while seven originated from Japan. The Caucasian samples were
snap-frozen and stored at –70° C prior to analysis. The tumours
were examined by standard histological examination and classi-
fied according to the systems used in the respective regions of
origin (Morita et al, 1983; Weinberg and Finegold, 1983). The
Caucasian samples were freeze-sectioned into 1 mm portions
interrupted by 5 µ m sections. Histopathological analysis was
carried out on the 5 µ m sections to obtain tissue profiles as
described previously (Gray et al, 2000).
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Comparative genomic hybridization
Genomic DNA was prepared by repeated phenol/chloroform
extractions of tissue cells with 0.5% SDS and proteinase K 
(200 µ g/ml final concentration). CGH was performed as previ-
ously described (Kallioniemi et al, 1992). Briefly, tumour DNA
was labelled with FITC-dUTP (DuPont, Boston MA) by nick
translation, and normal reference DNA was labeled with Texas
Red (Vysis Inc., Downers Grove, IL, USA). Tumour and reference
DNA were mixed with unlabelled Cot-1 DNA (Gibco, BRL),
denatured, and applied onto slides with denatured metaphases of
normal lymphocytes (Vysis Inc. Downers Grove, IL, USA). Using
a commercial hybridization solution (Vysis Inc. Downers Grove,
IL, USA), the slides were hybridized at 37° C for 48 h, and then
were washed in 0.4 × SSC/0.3% NP-40 at 74° C for 2 mins and in
2 × SSC/0.1% NP-40 at room temperature for 1 min. After air
drying, the slides were counterstained with DAPI (Vysis Inc.
Downers Grove, IL, USA). Ten three-colour digital images
(DAPI, FITC, and Texas Red fluorescence) were collected from
the hybridizations using a Zeiss Axioplan 2 (Carl Zeiss Jena
GmbH, Jena, Germany) epifluorescence microscope and Sensys
(Photometrics) charge-coupled-device camera interfaced to a
IPLab Spectrum 10 workstation (Signal Analytics Corporation,
Vienna, VA, USA). Green-to-red ratios > 1.15 were considered as
gains of genetic material, and ratios < 0.85 as losses. A green to
red ratio > 1.5 was considered to be a high level amplification
event. Heterochromatic regions, the short arm of the acrocentric
chromosomes and chromosome Y were not included in the evalu-
ation. Two control experiments were also performed. In the first,
DNA from a normal male and DNA from a normal female were
labelled and hybridized to normal male metaphases. For the
second experiment DNA from a previously characterized breast
cancer cell line (MPE600, Vysis Inc.) and DNA from a normal
female were labelled and hybridized to normal male
metaphases.
Statistical analysis
Statistical analysis was carried out using StatView© (SAS
Institute Inc., San Francisco, CA), and the analytical method used
to examine the differences between genetic losses and gains based
on ethnic background was the Fishers Exact Test.
RESULTS
Comparative genomic hybridization analysis
We used CGH to identify any chromosomal gains or losses in a
series of sporadic hepatoblastomas (Table 1). The results are
shown graphically in Figure 1, and have been tabulated for each
individual tumour in Table 2. The minimal regions of losses for the
most frequently altered chromosomes were 9p22-pter (22%), and
13q21–q22 (28%). The minimal regions of gain were 1q24–q25
(28%), 2q23–q24 (33%) and 20q (28%). In some of the samples
showing gain of 2q, a distinct amplification of the region between
2q22–q24 was observed (Figure 2.) Four individuals were found to
have no genetic losses or gains (Table 2).
One problem associated with the comparative genomic
hybridization technique has been the problem of differential
labelling of specific chromosomal regions. Such regions
commonly include distal 1p, 22 and 16p (Larramendy et al, 1998).
Our analysis of these samples revealed frequent losses involving
chromosomes 1p (44%) and 16p (22%) using CGH. When we
tested the samples for which we had matched normal liver from
the same individual for loss of heterozygosity (LOH) at 1p, we
were unable to demonstrate any LOH for the samples tested (data
not shown). As such, any losses or gains involving this region, and
for those of chromosomes 16p, 22 and the X chromosome were
considered suspect, and discarded from the overall analysis.
However, 1p LOH has been shown to occur in hepatoblastomas
(Kraus et al, 1996), and thus the losses observed using CGH for
these chromosomal regions, may represent submicroscopic or
balanced genetic alterations in these samples.
Table 1 Clinical data for the tumour samples used in this study
Case Ethnic Age at Sex Histopathological Pre-operative
No. origin dignosis M/F subtype chemotherapy
(months)
1 Caucasian 6 M Epithelial No
2 Caucasian 19 M Epithelial Yes
3 Caucasian 19 M Epithelial Yes
4 Caucasian 22 M Epithelial/mesenchymal Yes
5 Caucasian 54 M Epithelial Yes
6 Caucasian 2 M Fetal No
7 Caucasian 12 F Fetal Yes
8 Caucasian 36 M N/A Yes
9 Caucasian 11 F Fetal No
10 Caucasian 13 M Fetal No
11 Caucasian 8 F Epithelial/mesenchymal No
12 Japanese 21 M Fetal Yes
13 Japanese 162 F Embryonal Yes
14 Japanese 19 M Embryonal Yes
15 Japanese 33 F Anaplastic No
16 Japanese 29 M Fetal No
17 Japanese 30 M Embryonal Yes
18 Japanese 23 F Fetal Yes
N/A – not available; M – Male; F – FemaleComparison of alterations in hepatoblastomas on the
basis of ethnicity
We separated the genetic alterations in the primary tumours on the
basis of ethnicity, to see if any significant patterns emerged. The
results of this analysis are presented in Table 3. Several alterations
occurred in the Japanese samples which were not present in
the Caucasian samples. These were loss of 4q and 13q,
and gain of chromosome 19. When we tested if any of these
alterations were significant, only one, gain of 13q, was demon-
strated to be statistically significant. The CGH profiles obtained
for chromosome 13 in the Japanese samples are provided in
Figure 3.
DISCUSSION
Comparative genomic hybridization (CGH) was used to examine
the samples for chromosomal losses and gains. Numerical imbal-
ances were detected in the vast majority of cases (14/18). In the
four cases without demonstratable chromosomal imbalances,
submicroscopic or balanced genetic alterations cannot be ex-
cluded. In our samples, the most frequent losses found involved
chromosomes 9 and 13. The most frequent gains occurred on chro-
mosomes 1, 2 and 20. Other CGH analyses of hepatoblastomas
have been reported recently. The results confirm the importance of
chromosomes 1, 2, and 20 in hepatoblastoma (Steenman et al,
1999; Hu et al, 2000).
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Figure 1 DNA copy number changes detected by CGH in the hepatoblastoma samples. Each line represents one alteration detected in a tumour, with losses
illustrated to the left and gains to the right of the ideogramsCGH analysis of hepatoblastomas 1023
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A hypothetical cytogenetic pattern of evolution for hepato-
blastomas was proposed by Sainati and colleagues, for a subgroup
of hepatoblastomas which suggested that the initial event was gain
of chromosome 20, followed by gain of either chromosome 8 or
chromosome 2 and leading to late gains of chromosomes 1 (1q21),
7 and 19 (Sainati et al, 1998). The results obtained in this study
do not agree with this hypothetical pattern and suggest that
multiple pathways may be involved with the development of
hepatoblastoma.
A major difference between our analysis and the other CGH
reports is that few genetic losses were observed in their samples,
while many losses were observed in ours (Figure 1, Table 2). It is
possible that many of the alterations observed may be due to the
pre-operative chemotherapy (Table 1). However, individual Case
10 who did not receive any chemotherapy, has two chromosomal
abnormalities as detected by CGH.
Very few alterations to 13q have been reported (Nagata et al,
1999). Our results however, demonstrate the importance of chro-
mosome 13q in this tumour type. Five of our samples (28%) have
a loss of all or part of chromosome 13q (Figure 3). The minimal
region of loss in these samples is 13q21–q22. A review of the
literature shows that the region encompassing 13q21 is frequently
lost in 32 of 73 (47%) of all cancers examined using CGH
(Knuutila et al, 1999). Thus, an important gene such as a tumour
suppressor may lie within this chromosomal region.
T
a
b
l
e
 
2
L
o
s
s
e
s
 
a
n
d
 
g
a
i
n
s
 
o
n
 
t
h
e
 
m
o
s
t
 
f
r
e
q
u
e
n
t
l
y
 
i
n
v
o
l
v
e
d
 
c
h
r
o
m
o
s
o
m
e
 
a
r
m
s
 
i
n
 
r
e
l
a
t
i
o
n
 
t
o
 
t
h
e
 
t
o
t
a
l
 
n
u
m
b
e
r
 
o
f
 
a
l
t
e
r
a
t
i
o
n
s
 
i
n
 
t
h
e
 
t
u
m
o
r
.
 
T
h
e
 
m
i
n
i
m
a
l
 
r
e
g
i
o
n
s
 
i
n
v
o
l
v
e
d
 
a
r
e
 
i
n
d
i
c
a
t
e
d
C
a
s
e
N
o
 
o
f
2
q
2
3
–
q
2
4
2
0
q
1
q
2
4
–
q
2
5
1
3
q
2
1
–
q
2
2
9
q
2
2
–
p
t
e
r
1
8
q
1
1
q
1
4
–
q
t
e
r
3
q
2
3
–
q
2
5
O
t
h
e
r
 
g
a
i
n
s
O
t
h
e
r
 
l
o
s
s
e
s
N
o
.
c
h
a
n
g
e
s
g
a
i
n
s
g
a
i
n
s
g
a
i
n
s
l
o
s
s
e
s
l
o
s
s
e
s
l
o
s
s
e
s
l
o
s
s
e
s
l
o
s
s
e
s
0
0
0
0
1
2
q
2
2
–
q
2
4
1
2
0
4
q
1
2
2
q
2
2
–
q
3
1
1
q
2
3
–
q
3
1
2
2
1
q
2
1
–
q
t
e
r
2
1
3
q
2
1
–
q
t
e
r
1
2
p
2
1
q
2
4
–
q
2
5
8
p
3
2
1
8
q
7
q
3
1
4
1
3
q
2
1
–
q
2
2
1
1
q
1
4
–
q
t
e
r
9
q
3
2
–
q
t
e
r
,
 
1
9
4
2
0
1
3
q
2
1
–
q
2
2
9
p
2
2
–
q
t
e
r
3
q
2
3
–
q
2
5
5
2
q
2
3
–
q
3
2
2
0
p
2
p
1
3
–
p
t
e
r
,
 
9
q
3
2
–
q
t
e
r
,
 
1
2
q
2
2
–
q
t
e
r
7
2
0
q
1
3
q
2
1
–
q
2
2
9
p
8
q
2
q
2
2
,
 
4
q
2
5
–
q
t
e
r
,
 
8
p
8
2
0
1
q
2
1
–
q
t
e
r
9
1
8
p
1
1
q
1
4
–
q
t
e
r
3
1
4
,
 
1
5
q
1
5
2
q
2
3
–
q
t
e
r
2
0
q
1
q
1
3
q
2
1
–
q
2
2
9
p
t
e
r
–
q
3
1
1
8
1
1
q
1
4
–
q
t
e
r
3
1
7
q
2
2
–
q
t
e
r
,
 
1
9
4
q
2
1
–
q
t
e
r
,
 
6
q
1
6
–
q
t
e
r
,
 
1
1
c
–
p
1
4
,
 
1
4
q
1
2
–
q
2
1
,
 
2
1
q Case 4
n=13 2
Case 8
n=10 2
Case 9
n=14 2
Case 11
n=17 2
Figure 2 Gains of chromosome 2 in hepatoblastomas. CGH ideograms and
profiles for representative samples showing gains of chromosome 2 are
presented. For Case 11, a distinct amplification of the region between 2q22-
q24 was observed, and the digitized fluorescent image of chromosome 2
from this individual is also shown
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Figure 3 Losses of chromosome 13 in hepatoblastomas. CGH ideograms
and profiles for Japanese samples showing loss of chromosome 13 q
presented
Table 3 The most frequent CGH alterations in hepatoblastomas from
Caucasian and Japanese cases
Caucasian Japanese P valuea Total
Gain of 2q23–q24 4/11 (36%) 2/7 (29%) n.s 6/18 (33%)
Gain of 20 q 2/11 (18%) 3/7 (43%) n.s 5/18 (28%)
Gain of 1q24–q25 4/11 (36%) 1/7 (14%) n.s 5/18 (28%)
Loss of 13q21–q22 0/11 (0%) 5/7 (71%) 0.025 5/18 (28%)
Loss of 9p22-pter 1/11 (9%) 3/7 (43%) n.s 4/18 (22%)
an.s = not significant
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One individual, Case 11, has only one genetic alteration which
involves gain of 2q22–q24 (Table 2). The gain of 2q may play a
significant role in hepatoblastoma development, since in addition
to this individual, several others were found with a gain of
2q22–q32 (Table 2, Figure 2). Several other papers have shown
trisomy 2 and partial trisomy of 2q in hepatoblastoma (Nagata et
al, 1999). More significantly, structural abnormalities involving 2q
have also been reported involving the region of 2q (2q23–q32),
which we have observed to be amplified (Nagata et al, 1999) indi-
cating that this region may be very important in the development
of hepatoblastomas. A recent analysis of hepatoblastomas using
CGH by Perlman and colleagues has also demonstrated a high
level amplification of this region (Hu et al, 2000). One investiga-
tion examining the amplification of several well characterized
oncogenes such as N-MYC was unable to find any amplification in
hepatoblastomas (Mares et al, 1998). If this amplification is due to
the presence of a potential oncogene, a possible candidate gene
may be the fibroblast activation protein alpha (FAP) which has
been mapped to 2q23 (Mathew et al, 1995). This is a cell surface
antigen shown to be selectively expressed in several cancers, but
has also been shown to be transiently expressed in fetal
mesenchymal tissues (Scanlan et al, 1994). The FAP protein is a
surface bound serine protease and has been proposed to play a role
in the invasion of cancer cells into the extracellular matrix (Chen,
1996).
Another potential candidate may be a multiple drug resistance
(MDR) gene. Recently, a CGH study examining the genetic
changes in human ovarian carcinoma cell lines resistant to
cisplatin found that gain of region 2q14.1–q33 occurred in 5 of 6
cell lines examined (Wasenius et al, 1997). The gene for MDR1
encodes a p-glycoprotein and belongs to the ATP-binding cassette
(ABC) transporter. A novel liver specific ABC transporter BSEP,
was recently identified and maps to 2q24, and is involved in a rare
childhood liver disorder, in progressive familial intrahepatic
cholestasis (PFIC) (Strautnieks et al, 1998). Thus, the frequent
alterations to chromosome 2 frequently observed in hepatoblas-
tomas, involving trisomies, amplifications, and translocations,
may relate to drug resistance being engendered by the pre-
operative treatment of the individuals.
However, two of the individuals who did not receive any
chemotherapy prior to surgery also have gains within this region
(Table 1, Table 2), and therefore, it seems more likely, that if the
candidate gene BSEP is involved in hepatoblastoma development,
it may be through a defect in its function as the major canicular
bile salt export pump. Gain of 2q22–q24 in hepatoblastomas may
be of critical importance in the development or pathogenesis of
this tumour. Because chromosome 2q is so frequently altered in
hepatoblastomas, a concerted effort should be undertaken to
determine the gene involved.
Finally, we have demonstrated an ethnographical difference in
hepatoblastomas. Loss of 13q only occurs in the Japanese samples.
The significance of this is currently unknown. One possibility may
be hepatitis infection, although this is not common in Japan.
Hepatocellular carcinoma (HCC) is frequently associated with
hepatitis infections. Several studies-have demonstrated that loss of
chromosome 13q is frequent in HCCs (ranging between
20–32.4%) (Nagai et al, 1997; Lin et al, Sakakura et al, 1999; Sheu
et al, 1999). However, there has been no correlation between loss
of 13q and hepatitis, and in two studies, loss of 16q appears to be
the most significant genetic abnormality associated with hepatitis
infected HCC (Lin et al, 1999; Sheu et al, 1999). The samples from
Japan used in our study were all hepatitis B antigen (HBs-Ag)
negative, indicating that hepatitis B is not a factor. Some of the
samples have also been tested for hepatitis C (HCV). Of the ones
tested, only sample 12 was positive for HCV. The other samples
tested for HCV (samples 17–19) were negative. Thus, the loss of
13q may not be related to hepatitis C infection as one of the
samples tested (sample 18) was HCV negative while one (sample
12) was HCV positive.
Clearly, a much larger study using CGH should be undertaken
for hepatoblastomas to define more clearly the genetic alterations
in hepatoblastoma for both general and demographic or regional
alterations.
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